Caracterización de la resistencia antimicrobiana en el ámbito hospitalario y aportes de las acciones PROA y CAB, Bogotá 2019 a 2023

Authors

  • Luz Amparo Sastoque Diaz Secretaría Distrital de Salud Author
  • Paola Carolina Correal Tovar Secretaría Distrital de Salud Author https://orcid.org/0009-0001-2376-2185
  • Yaniz Rocio Hernández Gonzalez Secretaría Distrital de Salud Author

DOI:

https://doi.org/10.56085/bed.600

Keywords:

resistencia antimicrobiana, hospitalario, antibióticos, optimización, Enterobacterales, carbapenémicos

Abstract

Antimicrobial resistance (AMR) is a serious global threat to human health, particularly in hospital settings, where the high and sometimes inappropriate use of antibiotics accelerates its progression. Studies have evaluated the impact of AMR on incidence rates, mortality, length of hospital stays, and healthcare costs for specific pathogen–drug combinations. In the District of Bogotá, a marked increase in resistance to carbapenems was observed between 2021 and 2023 in both Intensive Care Unit (ICU) and non-ICU
settings for Klebsiella pneumoniae, with 40 % coproduction of KPC-NDM-SHV and 18.6 % KPC-NDM in 2023. According to the literature, risk factors for acquiring carbapenemase-producing microorganisms include comorbidities, prolonged hospital stays, the
use of invasive devices and supportive therapies, and the extended administration of broad-spectrum antibiotics. This situation was further exacerbated by the COVID-19 pandemic, which caused significant strain on healthcare services, particularly in 2021.

Downloads

Download data is not yet available.

Author Biographies

  • Luz Amparo Sastoque Diaz, Secretaría Distrital de Salud

    Subdirección Vigilancia en Salud Pública.

  • Paola Carolina Correal Tovar, Secretaría Distrital de Salud

    Subdirección Vigilancia en Salud Pública.

  • Yaniz Rocio Hernández Gonzalez, Secretaría Distrital de Salud

    Subdirección Vigilancia en Salud Pública.

References

World Health Organization. Plan de acción mundial sobre la resistencia a los antimicrobianos. Ginebra: Organización Mundial de la Salud; 2016. ISBN: 978 92 4 350976 1

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. [Internet]. 2022; 399(10325): 629-55. Disponible en: https://doi.org/10.1016/S0140-6736(21)02724-0

European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe. [Internet]. 2022. Disponible en: https://iris.who.int/handle/10665/351141

Centers for Disease Control and Prevention. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. [Internet]. Atlanta, Georgia; 2022. Disponible en: https://stacks.cdc.gov/view/cdc/117915

Instituto Nacional de Salud. Vigilancia por laboratorio de resistencia antimicrobiana en infecciones asociadas a la atención en salud (IAAS). Colombia, años 2012 a 2020. Bogotá: Instituto Nacional de Salud; 2021.

Secretaría Distrital de Salud. Boletín distrital resistencia bacteriana. Colombia, 2017-2021. Bogotá: Secretaría Distrital de Salud; 2021. https://doi.org/10.56085/01238590.215

Instituto Nacional de Salud. Informe técnico del evento de vigilancia por Whonet de resistencia antimicrobiana en el ámbito hospitalario. [Internet]. Colombia, 2022 Bogotá: Instituto Nacional de Salud; 2022. Disponible en: https://www.ins.gov.co/BibliotecaDigital/vigilancia-por-whonet-de-resistencia-antimicrobiana-en-el-ambito-hospitalario-colombia-2022.pdf, https://doi.org/10.33610/858878jgmyhe

World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. Geneva: World Health Organization; 2022. Disponible en: https://www.who.int/publications/i/item/9789240062702

Centros para el Control y la Prevención de Enfermedades. COVID-19: impacto en la resistencia a los antimicrobianos en los EE. UU., Informe especial del 2022 [Internet]. Disponible en: https://www.cdc.gov/antimicrobial-resistance/media/pdfs/covid19-impact-report-508.pdf

Centers for Disease Control and Prevention. Carbapenem-Resistant-Enterobacterales. [Internet]. Disponible en: https://arpsp.cdc.gov/profile/arln/cre?tabsection-163=0&hidden=

Robertson J, Trost M, Wong G, Jaki T. Changes in hospital antibiotic consumption during the COVID-19 pandemic. Antimicrob Resist Infect Control. [Internet]. 2021; 10(1): 87. Disponible en: https://doi.org/10.1186/s13756-021-00987-6

González-Martín C, del Mar TM, Galán-Sánchez F, Sánchez-Hernández N, Cantón R. Impacto de la pandemia de COVID-19 en el consumo de antibióticos y la resistencia antimicrobiana en España. Rev Esp Quimioter. [Internet]. 2023; 36(1): 55-61. Disponible en: https://doi.org/10.37201/re.q.2023.2301

Klein EY, Van Boeckel TP, Martinez EM, Pant S, Laxminarayan R. Global trends in antibiotic consumption and resistance during the COVID-19 pandemic. J Glob Antimicrob Resist. [Internet]. 2023; 32: 102-10. Disponible en: https://doi.org/10.1016/j.jgar.2022.12.003

Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet Infect Dis. [Internet]. 2022; 10(11): 1182-90. Disponible en: https://doi.org/10.1016/S1473-3099(10)70270-6

Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. Relationship between antibiotic consumption and antibiotic resistance in Escherichia coli: a systematic review. Antimicrob Resist Infect Control. [Internet]. 2020; 3(1): 1-25. Disponible en: https://doi.org/10.1186/s13756-014-0021-0

Downloads

Published

2024-11-30

Issue

Section

Artículo central

How to Cite

Caracterización de la resistencia antimicrobiana en el ámbito hospitalario y aportes de las acciones PROA y CAB, Bogotá 2019 a 2023. (2024). Boletín Epidemiológico Distrital - BED, 21(11), 5-20. https://doi.org/10.56085/bed.600

Similar Articles

1-10 of 18

You may also start an advanced similarity search for this article.